Cancer Stage Compared With Mortality as End Points in Randomized Clinical Trials of Cancer Screening
JAMA · 11.06.2024 · 331 (22) · 1910
DOI: 10.1001/jama.2024.5814 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JAMA, erschienen am 11.06.2024. Verfasst von Xiaoshuang Feng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France. Hauptthemen laut MEDLINE: Early Detection of Cancer, Neoplasm Staging, Neoplasms, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 94-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: World Health Organization, NCI NIH HHS.
Abstract (Originalsprache)
Importance Randomized clinical trials of cancer screening typically use cancer-specific mortality as the primary end point. The incidence of stage III-IV cancer is a potential alternative end point that may accelerate completion of randomized clinical trials of cancer screening.
Objective
To compare cancer-specific mortality with stage III-IV cancer as end points in randomized clinical trials of cancer screening. Design, Setting, and Participants This meta-analysis included 41 randomized clinical trials of cancer screening conducted in Europe, North America, and Asia published through February 19, 2024. Data extracted included numbers of participants, cancer diagnoses, and cancer deaths in the intervention and comparison groups. For each clinical trial, the effect of screening was calculated as the percentage reduction between the intervention and comparison groups in the incidence of participants with cancer-specific mortality and stage III-IV cancer. Exposures Randomization to a cancer screening test or to a comparison group in a clinical trial of cancer screening. Main Outcomes and Measures End points of cancer-specific mortality and incidence of stage III-IV cancer were compared using Pearson correlation coefficients with 95% CIs, linear regression, and fixed-effects meta-analysis.
Results
The included randomized clinical trials tested benefits of screening for breast (n = 6), colorectal (n = 11), lung (n = 12), ovarian (n = 4), prostate (n = 4), and other cancers (n = 4). Correlation between reductions in cancer-specific mortality and stage III-IV cancer varied by cancer type ( I 2 = 65%; P = .02). Correlation was highest for trials that screened for ovarian (Pearson ρ = 0.99 [95% CI, 0.51-1.00]) and lung (Pearson ρ = 0.92 [95% CI, 0.72-0.98]) cancers, moderate for breast cancer (Pearson ρ = 0.70 [95% CI, −0.26 to 0.96]), and weak for colorectal (Pearson ρ = 0.39 [95% CI, −0.27 to 0.80]) and prostate (Pearson ρ = −0.69 [95% CI, −0.99 to 0.81]) cancers. Slopes from linear regression were estimated as 1.15 for ovarian cancer, 0.75 for lung cancer, 0.40 for colorectal cancer, 0.28 for breast cancer, and −3.58 for prostate cancer, suggesting that a given magnitude of reduction in incidence of stage III-IV cancer produced different magnitudes of change in incidence of cancer-specific mortality ( P for heterogeneity = .004). Conclusions and Relevance In randomized clinical trials of cancer screening, incidence of late-stage cancer may be a suitable alternative end point to cancer-specific mortality for some cancer types, but is not suitable for others. These results have implications for clinical trials of multicancer screening tests.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.
- Department of Respiratory Medicine, Leeds Teaching Hospitals, St James's University Hospital, Leeds, United Kingdom.
- Leeds Institute of Health Sciences, University of Leeds, Leeds, United Kingdom.
- Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington.
- Center for Early Detection Advanced Research, Knight Cancer Institute, Portland, Oregon.
Förderung
- World Health Organization
- NCI NIH HHS
Zitieren
APA
Feng, X., Zahed, H., Onwuka, J., Callister, M. E. J., Johansson, M., Etzioni, R., & Robbins, H. A. (2024). Cancer Stage Compared With Mortality as End Points in Randomized Clinical Trials of Cancer Screening. JAMA, 331(22), 1910. https://doi.org/10.1001/jama.2024.5814
Vancouver
Feng X, Zahed H, Onwuka J, Callister MEJ, Johansson M, Etzioni R, et al. Cancer Stage Compared With Mortality as End Points in Randomized Clinical Trials of Cancer Screening. JAMA. 2024;331(22):1910. doi:10.1001/jama.2024.5814
BibTeX
@article{Feng2024,
author = {Feng, Xiaoshuang and Zahed, Hana and Onwuka, Justina and Callister, Matthew E J and Johansson, Mattias and Etzioni, Ruth and Robbins, Hilary A},
title = {Cancer Stage Compared With Mortality as End Points in Randomized Clinical Trials of Cancer Screening},
journal = {JAMA},
year = {2024},
volume = {331},
number = {22},
pages = {1910},
doi = {10.1001/jama.2024.5814}
}
EUVIMED